Document is current

Article History

Received: 8 February 2023

Accepted: 21 August 2023

First Online: 14 September 2023

Declarations

:

: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

: Dr. Basho is an employee of The Lawrence J. Ellison Institute for Transformative Medicine (EITM), a public good for profit (the Institute comprises both a for-profit entity, whose profits will be reinvested into future public health and disease research, and a not-for-profit research foundation), which draws collaborators from across conventional health fields, as well as from a broad range of other disciplines, to study disease and potential ways to prevent, detect, and treat disease. Dr. Basho has served as a consultant for Pfizer, AstraZeneca, Seagen, Gilead, Novartis (uncompensated), and Genentech (uncompensated). She has been a paid speaker for MJH Healthcare, WebMD/Medscape, Eli Lilly, and Seagen. Dr. Basho has received research support (to the Cedars-Sinai institution) from Merck, Takeda, Eli Lilly, Pfizer, and Seagen. Megan-Claire Chase does not have any disclosures to report.

: This article does not contain any new studies with human participants or animals performed by any of the authors.

: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.